Shannon R Kenney1, Bradley J Anderson2, Genie L Bailey3, Michael D Stein4. 1. Behavioral Medicine Department, Butler Hospital, Providence, RI 02906, United States; Warren Alpert Medical School of Brown University, Providence, RI, 02912, United States. Electronic address: Shannon_Kenney@Brown.edu. 2. Behavioral Medicine Department, Butler Hospital, Providence, RI 02906, United States. 3. Warren Alpert Medical School of Brown University, Providence, RI, 02912, United States; Stanley Street Treatment and Resources, Inc., Fall River, MA 02720, United States. 4. Behavioral Medicine Department, Butler Hospital, Providence, RI 02906, United States; Boston University School of Public Health, Boston, MA 02118, United States.
Abstract
INTRODUCTION: Naloxone is a safe and effective antidote for reversing opioid overdose. Layperson administration of naloxone is increasingly common, yet little is known about demographic and clinical factors associated with opioid users' likelihood of having administered naloxone to another opioid user who had overdosed. We examined predictors of reported naloxone administration in the past year. METHODS: Four hundred and sixty-eight patients were interviewed upon admission to brief, inpatient opioid detoxification between May and December of 2015. Between group differences were tested using t-tests for differences in means and χ2-tests for differences in counts. RESULTS: Participants averaged 32years of age, 28.9% were female, and 86.8% were White. Most (86.8%) reported detoxifying from heroin, 69.0% had injected drugs in the last 30days. One sixth (n=68) of those detoxifying from heroin, but none of those detoxifying from other opioids (n=62) had administered naloxone in the past year. Among the small number of Black/African American participants (n=20), none had administered naloxone, although 90% were heroin users. Respondents were more likely to have administered naloxone if they reported recent injection drug use (IDU), had a history of overdose, or witnessed an overdose in the past year (ps<0.05), even though less than one-third of bystanders of overdose reported administering naloxone. CONCLUSIONS: Higher opioid-related mortality risk (heroin use, IDU, past overdose) was associated with greater likelihood of reported naloxone administration in the past year. The non-use of naloxone among certain groups-prescription pill users and Blacks-was unexpected.
INTRODUCTION:Naloxone is a safe and effective antidote for reversing opioid overdose. Layperson administration of naloxone is increasingly common, yet little is known about demographic and clinical factors associated with opioid users' likelihood of having administered naloxone to another opioid user who had overdosed. We examined predictors of reported naloxone administration in the past year. METHODS: Four hundred and sixty-eight patients were interviewed upon admission to brief, inpatient opioid detoxification between May and December of 2015. Between group differences were tested using t-tests for differences in means and χ2-tests for differences in counts. RESULTS:Participants averaged 32years of age, 28.9% were female, and 86.8% were White. Most (86.8%) reported detoxifying from heroin, 69.0% had injected drugs in the last 30days. One sixth (n=68) of those detoxifying from heroin, but none of those detoxifying from other opioids (n=62) had administered naloxone in the past year. Among the small number of Black/African American participants (n=20), none had administered naloxone, although 90% were heroin users. Respondents were more likely to have administered naloxone if they reported recent injection drug use (IDU), had a history of overdose, or witnessed an overdose in the past year (ps<0.05), even though less than one-third of bystanders of overdose reported administering naloxone. CONCLUSIONS: Higher opioid-related mortality risk (heroin use, IDU, past overdose) was associated with greater likelihood of reported naloxone administration in the past year. The non-use of naloxone among certain groups-prescription pill users and Blacks-was unexpected.
Authors: Kristen C Ochoa; Peter J Davidson; Jennifer L Evans; Judith A Hahn; Kimberly Page-Shafer; Andrew R Moss Journal: Drug Alcohol Depend Date: 2005-06-14 Impact factor: 4.492
Authors: Michael A Yokell; M Kit Delgado; Nickolas D Zaller; N Ewen Wang; Samuel K McGowan; Traci Craig Green Journal: JAMA Intern Med Date: 2014-12 Impact factor: 21.873
Authors: Andrew Rosenblum; Mark Parrino; Sidney H Schnoll; Chunki Fong; Carleen Maxwell; Charles M Cleland; Stephen Magura; J David Haddox Journal: Drug Alcohol Depend Date: 2007-03-26 Impact factor: 4.492
Authors: Stephen E Lankenau; Karla D Wagner; Karol Silva; Aleksandar Kecojevic; Ellen Iverson; Miles McNeely; Alex H Kral Journal: J Community Health Date: 2013-02
Authors: Brent A Moore; David A Fiellin; Declan T Barry; Lynn E Sullivan; Marek C Chawarski; Patrick G O'Connor; Richard S Schottenfeld Journal: J Gen Intern Med Date: 2007-04 Impact factor: 5.128
Authors: Maya Doe-Simkins; Emily Quinn; Ziming Xuan; Amy Sorensen-Alawad; Holly Hackman; Al Ozonoff; Alexander Y Walley Journal: BMC Public Health Date: 2014-04-01 Impact factor: 3.295
Authors: Lauren Dayton; Rachel E Gicquelais; Karin Tobin; Melissa Davey-Rothwell; Oluwaseun Falade-Nwulia; Xiangrong Kong; Michael Fingerhood; Abenaa A Jones; Carl Latkin Journal: PLoS One Date: 2019-11-07 Impact factor: 3.752
Authors: Lauren Lipira; Gillian Leichtling; Ryan R Cook; Judith M Leahy; E Roberto Orellana; P Todd Korthuis; Timothy W Menza Journal: Drug Alcohol Depend Date: 2021-07-21 Impact factor: 4.852